iX Biopharma Ltd. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of therapies for the treatment of acute and breakthrough pain, and male erectile dysfunction. Its segments include Specialty Pharmaceutical and Chemical Analysis segments. The Specialty Pharmaceutical segment is engaged in the development, manufacturing and sale of pharmaceutical products. The Chemical Analysis segment is engaged in the provision of laboratory testing services. Its products are Wafermine, which is a sublingual ketamine oral wafer that contains the non-opioid drug for the management of moderate to severe pain; Bnox, which is a sublingual buprenorphine oral wafer that is developed as a formulation for moderate to severe pain; PheoniX, which is used for the treatment of male erectile dysfunction; WaferRest, which is used for the alleviation of jet lag and improving sleep quality, and Wafernyl, which is used for breakthrough cancer pain.